QIAGEN führt CE-markierten molekularen Test auf Krebs-Biomarker K-ras ein
Test auf Basis der Pyrosequenzierungs-Technologie erlaubt Nachweis und Differenzierung von Genmutationen zur Prognose des Therapieerfolgs mit EGFR-Inhibitoren bei Darmkrebspatienten (pressebox) Venlo,...
View ArticleAmgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 – ESMO...
Thousand Oaks, California (ots/PRNewswire) – – Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented Amgen (Nasdaq: AMGN) today announced it will present detailed data from four Phase 3...
View ArticleVectibix(R) in Combination With Chemotherapy Significantly Improves...
Thousand Oaks, California (ots/PRNewswire) – Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘181’ trial evaluating Vectibix(R) (panitumumab) in combination with FOLFIRI (an...
View ArticleAmgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With...
Thousand Oaks, California (ots/PRNewswire) – Amgen today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European...
View ArticleAmgen to Appeal CHMP Opinion on Vectibix(R) (Panitumumab) Use With...
Thousand Oaks, California (ots/PRNewswire) – Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by...
View ArticleAmgen Establishes Commercial Operations in Brazil
Thousand Oaks, California (ots/PRNewswire) – Amgen , the world’s largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition of Bergamo, a...
View ArticleAmgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in...
Thousand Oaks, California (ots/PRNewswire) – Amgen today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...
View ArticleVectibix® (Panitumumab) Granted Approval for Expanded Indications in the...
Thousand Oaks, California, November 15 (ots/PRNewswire) – Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix(R) (panitumumab)...
View ArticleBluttest zur Früherkennung von Resistenzen bei Krebspatienten auf der Basis...
Baltimore/Hamburg (ots) – Gleich zwei Forschungsprojekte, die letzte Woche in der Online-Ausgabe des Fachmagazins Nature erschienen sind, befassen sich mit der Früherkennung von Wirkstoffresistenzen,...
View Article
